Epigenetics-based cervical cancer diagnostics
Cervical cancer is the fourth most common cancer in women worldwide. While HPV testing has dramatically improved early detection, HPV-positive results require further differentiation: not every HPV infection leads to cancer. oncgnostics' GynTect® test fills this gap.
GynTect® detects aberrant methylation of six epigenetic markers in cervical cells — patterns that are specifically associated with the development of cervical cancer. The test provides high specificity to identify which HPV-positive patients have cancer or high-grade precancerous lesions requiring immediate treatment.
Founded in Jena in 2012 from research at the Leibniz Institute on Aging (Fritz Lipmann Institute), oncgnostics has validated GynTect® in clinical studies across Europe and licensed the technology to partners in China and other markets. Dr. Peter Haug co-founded the company and led Business Development, contributing to Series A fundraising, crowdfunding campaigns and the China licensing deal.
Role of Dr. Peter Haug
- ✓ Co-Founder
- ✓ Head of Business Development
- ✓ Series A fundraising
- ✓ Crowdfunding campaigns (2x)
- ✓ International licensing (China)